



AtheroSclerotic CardioVascular Disease

Prevention

Dr. Alireza Moarref Associate Professor of Cardiology, Shiraz University of Medical Sciences








2020 ISH Global Hypertension Practice Guidelines

6th May 2020

www.ish-world.com





- L 110
- 1.39 billion estimated with hypertension in 2010
- 349 million from HIC ullet
- *Circulation.* 2016;134:441–450 1.04 billion from LMIC



- 140



Herein optimal care refers to *evidence-based standard* of care articulated in recent guidelines and summarized here, whereas **ESSENTIAL** standards recognize that **OPTIMAL** standards would not always be possible. Hence essential standards refer to minimum standards of care.





- 1. to be used globally
- 2. to be fit for application in low-resource and high- resource settings by advising on **ESSENTIAL** and **OPTIMAL** standards of care; and
- 3. to be concise, simplified and easy to use by clinicians, nurses and community health workers, as appropriate.





ESSENTIAL

Classification of hypertension based on Office blood pressure (BP) measurement

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal BP	< 130	and	< 85
High-normal BP	130–139	and/or	85-89
Grade 1 Hypertension	140–159	and/or	90-99
Grade 2 Hypertension	≥160	and/or	≥ 100





Category	Systolic (mmHg)		Diastolic (mmHg)
Normal BP	< 130	and	< 85
High-normal BP	130-139	and/or	85-89

High-normal BP is intended to identify individuals who could benefit from lifestyle interventions and who would receive pharmacological treatment if compelling indications are present.





Grade 1 Hypertension	140-159	and/or	90-99
Grade 2 Hypertension	≥160	and/or	≥100

Individuals identified with confirmed hypertension (grade 1 and grade 2) should receive appropriate pharmacological treatment.





ESSENTIAL

Hypertension based on Office-, Ambulatory (ABPM)and Home Blood Pressure (HBPM) measurement

SBP / DBP (mmHg)

Office BP		≥140 and/or ≥90
ABPM	24h average Day Time (or awake) average Night Time (or asleep) average	≥ 130 and/or ≥ 80 ≥ 135 and/or ≥ 85 ≥ 120 and/or ≥ 70
НВРМ		≥135 and/or ≥85






- 2-3 office visits at 1-4-week intervals.
- Whenever possible, the diagnosis should not be made on a single visit (unless BP ≥180/110 mmHg and CVD).
- If possible and available the diagnosis of hypertension should be confirmed by out- of-office measurement.



ESSENTIAL







OFFICE BP MEASUREMENT

Conditions	Device Protoco		Device Protoco	
Position	Cuff	Interpretation		
 Setting Body position Talking 	 Validated electronic upper-arm cuff (www.stridebp.org) Alternatively manual auscultatory device 	 Average 2nd-3rd measurement 2-3 office visits required 		
	Cuff size			





BP Measurement Plan according to Office BP levels

Office blood pressure levels (mmHg)			
<130/85 130-159/85-99 >160/100			
 Remeasure within 3 years (1 year if 	 If possible confirm with out-of-office measurement. 	 Confirm within a few days/weeks. 	
other risk factors).	 Alternatively confirm with repeated office visits. 		





Office Blood Pressure

Initial evaluation

 Measure BP in both arms. Difference >10 mmHg: use arm with higher BP; >20 mmHg: consider further investigation.

Standing BP

OPTIMAL

- In treated patients when symptoms of postural hypotension.
- At first visit in elderly and diabetics.

Unattended BP

- More standardized. Lower BP levels with uncertain threshold.
- Out-of-office BP again needed in most cases.





Out-of-Office Blood Pressure Measurement

	Home BP Monitoring	Ambulatory BP Monitoring
Conditions	As for office blood pressure (see above).	Routine working day.
Position	As for office BP (see above).	Avoid strenuous activity. Arm still and relaxed during each measurement.
Device		netric) upper-arm cuff device Section 11: Resources)
Cuff	Size according to the indiv	vidual's arm circumference
Measurement protocol		 24-hour monitoring at 15 – 30 min intervals during daytime and nighttime. At least 20 valid daytime and 7 nighttime BP readings are required. If less, the test should be repeated.
Interpretation	 Average home blood pressure after excluding readings of the first day ≥ 135 or 85mmHg indicates hypertension. 	 24-hour ambulatory blood pressure ≥ 130/80 mmHg indicates hypertension (primary criterion). Daytime (awake) ambulatory blood pressure ≥ 135/85 mmHg and nighttime (asleep) ≥ 120/70 mmHg indicates hypertension





White-coat Hypertension

- Intermediate CV risk.
- If low total CV risk and no organ damage, drug treatment may not be prescribed.
- Follow with lifestyle changes.

Masked Hypertension

- Similar CV risk as sustained hypertensives.
- Drug treatment may be required aiming to normalise out-of-office BP.





ESSENTIAL

- Medical History (BP, risk factors, co-morbidities, signs/symptoms of secondary hypertension...)
- Physical Examination (circulation, heart, other systems)
- Lab Investigations (Na+, K+, creatinine, eGFR, dipstick lipids, Fasting Glucose where available)
- 12 lead ECG (AF, LV hypertrophy, IHD...)

OPTIMAL

 Additional tests to consider (extended biochemistry, cardiac/kidney/brain/vascular imaging, fundoscopy...)





Most common medications that can increase BP

- Non-selective or traditional NSAIDs
- Combined oral contraceptive pill
- Select anti depressant medications including tricyclic antidepressants and SNRIs
- Acetaminophen when used almost daily and for prolonged periods
- Alcohol raises BP regardless of the type of alcoholic drink.





- 50% < hypertensive patients have additional CV risk factors.
- The most common additional risk factors are:







Cardiovascular Risk Factors

Other Risk Factors, HMOD, or Disease	SBF	ph-Normal 9 130–139 3P 85–89	Grade 1 SBP 140–159 DBP 90–99	Grade 2 SBP ≥160 DBP ≥100	
No other risk factors	Low		Low	Moderate Hi	
1 or 2 risk factors	Low		Moderate	High	
\geq 3 risk factors	Low Moderate		High	High	
HMOD, CKD grade 3, diabetes mellitus, CVD		High	High	High	





HMOD Assessment

ESSENTIAL

- Serum creatinine
- eGFR
- Dipstick urine test
- 12-lead ECG



- Brain
- Eyes
- Heart
- Kidneys
- Arteries

Serial assessment of HMOD


may help to determine efficacy of treatment





Treatment of Hypertension








JAMA November 6, 2018








BMC Cardiovasc Disord 2010; 10: 61

A 10 mm Hg reduction in systolic blood pressure can significantly reduce risk of several conditions:








- Lifestyle changes
- Pharmacological therapy



European Heart Journal (2018) 39, 3021–3104







BP = Blood pressure, BMI = Body mass index, SBP = Systolic blood pressure, DASH = Dietary Approaches to Stop Hypertension



Ideal Characteristics of Drug Treatment

1	Treatments should be evidence-based in relation to morbidity/mortality prevention.
2	Use a once-daily regimen which provides 24-hour blood pressure control.
3	Treatment should be affordable and/or cost-effective relative to other agents.
4	Treatments should be well-tolerated.
5	Evidence of benefits of use of the medication in populations to which it is to be applied.



Hypertension. 2020;75:1334-1357



Oral Antihypertensive Drugs


Primary agents


	Class	Drug	Daily Freq.
	Thiazide	Chlorthalidone	1
1	or Thiazide-type diuretics	Hydrochlorothiazide	1
		Indapamide	1
		Benazepril	1 or 2
2	ACE inhibitors	Captopril	2 or 3
		Enalapril	1 or 2
		Losartan	1 or 2
3	ARBs	Telmisartan	1
		Valsartan	1
	ССВ	Amlodipine	1
•	dihydropyridines	Nifedipine LA	1
4	ССВ	Diltiazem SR	2
	nondihydropyridines	Verapamil SR	1 or 2


Secondary agents

Class	Drug	Daily Freq.
Diuretics— loop	Furosemide	2
Diuretics	Amiloride	1 or 2
potassium sparing	Triamterene	1 or 2
Aldosterone antagonists	Spironolactone	1
	Atenolol	
	Bisoprolol	1
Beta blockers	Metoprolol tartrate	2
Beld DIOCKETS	Nebivolol	1
	Propranolol IR	2
	Carvedilol	2
Alpha-1 blockers	Terazosin	1 or 2
Control alpha1 aganist	Clonidine oral	2
Central alpha1 agonist	Methyldopa	2
Direct vasodilators	Hydralazine	2 or 3


Hypertension. 2018;71:e13-e115.








ISH core drug-treatment strategy






Consider ACEi or ARB + Thiazide in post-stroke, very elderly, incipient HF, or CCB intolerance.

ISH core drug-treatment strategy


Caution with spironolactone or other potassium-sparing diuretics when eGFR <45 mi/min/1.73m2 or K+ >4.5 mmol/L.



ISH core drug-treatment strategy

ESSENTIAL

- Consider **beta-blockers** at any treatment step when there is a specific indication for their use:
 - hear failure
 - Angina
 - post-MI
 - AF
 - younger women with, or planning pregnancy



Office blood pressure targets for treated hypertension

ESSENTIAL	Target BP reduction by at least 20/10 mmHg, ideally to <140/90 mmHg	Aim for BP control
OPTIMAL	<65 years : BP target <130 / 80 mmHg if tolerated (but >120 / 70 mmHg). ≥65 years : BP target <140 / 90 mmHg if tolerated but consider an individual- ised BP target in the context of frailty, independence and likely tolerability of treatment.	within 3 months



Adherence to Antihypertensive Treatment

- Nonadherence to antihypertensive treatment affects 10%–80% of hypertensive patients and is one of the key drivers of suboptimal BP control.
- Evaluate adherence to antihypertensive treatment as appropriate at each visit and prior to escalation of antihypertensive treatment.





Adherence to Antihypertensive Treatment

ESSENTIAL

Consider the following strategies to improve medication adherence:

- 1. reducing polypharmacy use of **single pill combinations**
- 2. once-daily dosing over multiple times per day dosing
- 3. linking adherence behavior with daily habits
- 4. providing adherence feedback to patients
- 5. home BP monitoring
- 6. reminder packaging of medications
- 7. empowerment-based counseling for self-management
- 8. electronic adherence aids such as mobile phones or short messages services
- 9. multidisciplinary healthcare team approach to improve monitoring for adherence

